Feeding Next‐Generation Nanomedicines to Europe: Regulatory and Quality Challenges
Advanced Healthcare Materials · 2023-12 · 12 (30)
DOI: 10.1002/adhm.202301956 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 17.09.2023. Verfasst von Umberto M Musazzi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Università degli Studi di Milano, via G. Colombo, Milan, 71-20133, Italy. Hauptthemen laut MEDLINE: Nanomedicine, Artificial Intelligence. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union-NextGenerationEU.
Abstract (Originalsprache)
New and innovative nanomedicines have been developed and marketed over the past half‐century, revolutionizing the prognosis of many human diseases. Although a univocal regulatory definition is not yet available worldwide, the term “nanomedicines” generally identifies medicinal products that use nanotechnology in their design or production. Due to the intrinsic high structural complexity of these products, the scientific and regulatory communities are reflecting on how to revise the regulatory framework to provide a more appropriate benefit/risk balance to authorize them on the market, considering the impact of their peculiar physicochemical features in the evaluation of efficacy and safety patterns. Herein, a critical perspective is provided on the current open issues regarding regulatory qualification and physicochemical characterization of nanosystems considering the current European regulatory framework on nanomedicine products. Practicable paths for improving their quality assurance and predicting their fate in vivo are also argued. Strengthening the multilevel alliance among academic institutions, industrial stakeholders, and regulatory authorities seems strategic to support innovation by standard approaches (e.g., qualification, characterization, risk assessment), and to expand current knowledge, also benefiting from the new opportunities offered by artificial intelligence and digitization in predictive modelling of the impact of nanomedicine characteristics on their fate in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, via G. Colombo, Milan, 71-20133, Italy.
- Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale, Largo Donegani, Novara, 2-28100, Italy.
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via F. Marzolo, Padova, 5-35131, Italy.
ORCID-Profile: Umberto M Musazzi, Silvia Franzè, Fabrizio Condorelli, Paola Minghetti, Paolo Caliceti
Förderung
- European Union-NextGenerationEU
Zitieren
APA
Musazzi, U. M., Franzè, S., Condorelli, F., Minghetti, P., & Caliceti, P. (2023). Feeding Next‐Generation Nanomedicines to Europe: Regulatory and Quality Challenges. Advanced Healthcare Materials, 12(30). https://doi.org/10.1002/adhm.202301956
Vancouver
Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding Next‐Generation Nanomedicines to Europe: Regulatory and Quality Challenges. Advanced Healthcare Materials. 2023;12(30). doi:10.1002/adhm.202301956
BibTeX
@article{Musazzi2023,
author = {Musazzi, Umberto M and Franzè, Silvia and Condorelli, Fabrizio and Minghetti, Paola and Caliceti, Paolo},
title = {Feeding Next‐Generation Nanomedicines to Europe: Regulatory and Quality Challenges},
journal = {Advanced Healthcare Materials},
year = {2023},
volume = {12},
number = {30},
doi = {10.1002/adhm.202301956}
}
EUVIMED